Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $77
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $77.
Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $75 to $77.